Compare KARD & NEOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KARD | NEOG |
|---|---|---|
| Founded | 2023 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.1B |
| IPO Year | 2026 | 1995 |
| Metric | KARD | NEOG |
|---|---|---|
| Price | $14.73 | $11.87 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $42.25 | $14.00 |
| AVG Volume (30 Days) | 648.9K | ★ 4.5M |
| Earning Date | 11-22-2026 | 10-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 99.20 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $870,400,000.00 |
| Revenue This Year | N/A | $1.68 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.23 | $5.37 |
| 52 Week High | $27.00 | $14.26 |
| Indicator | KARD | NEOG |
|---|---|---|
| Relative Strength Index (RSI) | 41.56 | 45.03 |
| Support Level | $13.75 | $8.67 |
| Resistance Level | $22.81 | $12.55 |
| Average True Range (ATR) | 1.27 | 0.80 |
| MACD | 0.11 | -0.22 |
| Stochastic Oscillator | 63.41 | 24.99 |
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, the company performs diagnostics to detect unintended substances in food and animal feed, to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. In animal safety, the company segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products and genomics testing services.